Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers, dialysis machines, hemodialysis machines, A.V. fistula needle sets, extracorporeal blood circuits, bloodlines, and plasma separators; peritoneal dialysis (PD) solutions; and PD consumables, such as bag free set, c… Read more
Shandong Weigao Blood (603014) - Net Assets
Latest net assets as of June 2025: CN¥6.80 Billion CNY
Based on the latest financial reports, Shandong Weigao Blood (603014) has net assets worth CN¥6.80 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.12 Billion) and total liabilities (CN¥1.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.80 Billion |
| % of Total Assets | 83.75% |
| Annual Growth Rate | 15.03% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.23 |
Shandong Weigao Blood - Net Assets Trend (2021–2024)
This chart illustrates how Shandong Weigao Blood's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shandong Weigao Blood (2021–2024)
The table below shows the annual net assets of Shandong Weigao Blood from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.60 Billion | +8.97% |
| 2023-12-31 | CN¥5.14 Billion | +10.05% |
| 2022-12-31 | CN¥4.67 Billion | +26.95% |
| 2021-12-31 | CN¥3.68 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Weigao Blood's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 419.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.33 Billion | 23.69% |
| Other Components | CN¥4.27 Billion | 76.31% |
| Total Equity | CN¥5.60 Billion | 100.00% |
Shandong Weigao Blood Competitors by Market Cap
The table below lists competitors of Shandong Weigao Blood ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EQMA3BF
SA:EQMA3BF
|
$52.15K |
|
Rank Group PLC
LSE:RNK
|
$52.15K |
|
Hollywood Bowl Group PLC
LSE:BOWL
|
$52.17K |
|
Israel China Biotechnology (ICB) Ltd
TA:ICB
|
$52.21K |
|
Veteranpoolen AB Series B
ST:VPAB-B
|
$52.14K |
|
Sporttotal AG
F:WIG1
|
$52.08K |
|
SUNOPTA - Dusseldorf Stock Exchang
DU:ZSK
|
$52.04K |
|
M'BISHI CHEM HLDGS
MU:M3C
|
$51.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Weigao Blood's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,136,299,600 to 5,596,777,565, a change of 460,477,965 (9.0%).
- Net income of 449,368,867 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥449.37 Million | +8.03% |
| Other Changes | CN¥11.11 Million | +0.2% |
| Total Change | CN¥- | 8.97% |
Book Value vs Market Value Analysis
This analysis compares Shandong Weigao Blood's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.76x to 2.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥10.50 | CN¥39.54 | x |
| 2022-12-31 | CN¥12.61 | CN¥39.54 | x |
| 2023-12-31 | CN¥13.87 | CN¥39.54 | x |
| 2024-12-31 | CN¥15.12 | CN¥39.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Weigao Blood utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.03%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.47%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.25x
- Recent ROE (8.03%) is above the historical average (7.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 7.07% | 8.93% | 0.49x | 1.62x | CN¥-107.83 Million |
| 2022 | 6.75% | 9.19% | 0.53x | 1.37x | CN¥-151.75 Million |
| 2023 | 8.61% | 12.52% | 0.53x | 1.30x | CN¥-71.56 Million |
| 2024 | 8.03% | 12.47% | 0.52x | 1.25x | CN¥-110.31 Million |
Industry Comparison
This section compares Shandong Weigao Blood's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Weigao Blood (603014) | CN¥6.80 Billion | 7.07% | 0.19x | $52.15K |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |